Pfizer Inc. (PFE) Shares Sold by Bainco International Investors
Bainco International Investors trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 30.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,322 shares of the biopharmaceutical company’s stock after selling 2,800 shares during the period. Bainco International Investors’ holdings in Pfizer were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer during the second quarter worth about $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer during the second quarter worth about $103,000. D. Scott Neal Inc. boosted its position in shares of Pfizer by 19.3% during the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Herndon Capital Management LLC acquired a new position in shares of Pfizer during the second quarter worth about $120,000. Finally, Lipe & Dalton boosted its position in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the period. 69.75% of the stock is owned by hedge funds and other institutional investors.
Shares of Pfizer Inc. (NYSE:PFE) opened at $36.86 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market capitalization of $219,710.00, a P/E ratio of 22.61, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.61 earnings per share. equities research analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.69%. Pfizer’s dividend payout ratio is currently 78.53%.
Pfizer announced that its board has initiated a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.
Several research analysts recently commented on the company. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a research report on Friday. Jefferies Group set a $38.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Monday, October 16th. BMO Capital Markets set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday, October 31st. Finally, Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday, September 19th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $38.88.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock worth $1,065,220 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/pfizer-inc-pfe-shares-sold-by-bainco-international-investors/1797805.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.